IASL 2021

PROGRAM

GMT+09:00 (Korea, Japan)

ROOM 1

Session 1

Unresolved Issues in Hepatitis B

Jul. 16 09:00-09:20

Immune Tolerance - Does It Exist and Shall We Treat?

Hye Won Lee (Yonsei University, Korea)

Jul. 16 09:20-09:40

How to Define and Manage Inactive Carriers?

Jia Horng Kao (National Taiwan University, Taiwan)

Jul. 16 09:40-10:00

Can Biomarkers Guide Stopping NA?

Jinlin Hou (Southern Medical University, China)

Jul. 16 10:00-10:20

Prophylaxis for Anti-HBc Positive Patients on Immunosuppression

Rajender Reddy (University of Pennsylvania, USA)

Jul. 16 10:20-10:40

Discussion

Session 3

HCV Cure - Are We Done?

Jul. 16 10:50-11:10

Is DAA for All HCV-Related HCC Patients - A Call for Expanded Use and the Point of "No Return"

Norah Terrault (Keck School of Medicine of USC, USA)

Jul. 16 11:10-11:30

DAA Treatment in Asia Pacific Region and Its Impact on Clinical Outcome

Sang Hoon Ahn (Yonsei University, Korea)

Jul. 16 11:30-11:50

HCV Treatment in Special Populations

Ed Gane (The University of Auckland, New Zealand)

Jul. 16 11:50-12:10

Roadmap to HCV Elimination in 2030

Nobuyuki Enomoto (University of Yamanashi, Japan)

Jul. 16 12:10-12:30

Discussion

Jul. 16 12:30-13:10

Lunch Break

IASL

Opening Ceremony & General Meeting

Jul. 16 13:10-13:25

Opening Remarks

Representative of IASL/EASL/AASLD/WGO

Jul. 16 13:25-13:35

Past of IASL

Samuel Lee, Past President

Jul. 16 13:35-13:45

General Meeting: IASL Report

Markus Peck, Secretary General

Jul. 16 13:45-13:50

Future of IASL

Markus Peck, President-Elect

Session 5

Emerging Issues in the Era of COVID-19

Jul. 16 14:00-14:20

Telemedicine in Resource Limited Setting

Marco Arrese (Pontificia Universidad Católica de Chile, Chile)

Jul. 16 14:20-14:40

COVID Vaccine for Liver Patients

Raymond Chung (Harvard Medical School, USA)

Jul. 16 14:40-15:00

Significance of Liver Injury in COVID-19 Patients

Qin Ning (Huazhong University of Science and Technology, China)

Jul. 16 15:00-15:20

Immunologic Approach for COVID-19

Mario Mondelli (University of Pavia, Italy)

Jul. 16 15:20-15:40

Discussion

Session 7

Challenges in Hepatitis and Liver Failure

Jul. 16 15:50-16:10

Acute Hepatitis E - Challenges in Diagnosis and Management

Heiner Wedemeyer (Hannover Medical School, Germany)

Jul. 16 16:10-16:30

Diagnostic Dilemma of Drug Induced Liver Injury

Alexander Gerbes (Ludwig-Maximilian-University of Munich, Germany)

Jul. 16 16:30-16:50

Hepatitis Delta - A Treatable Disease?

Cihan Yurdaydin (University of Ankara Medical School, Turkey)

Jul. 16 16:50-17:10

Acute on Chronic Liver Failure - When to Consider Liver Transplantation?

Saeed Hamid (The Aga Khan University, Pakistan)

Jul. 16 17:10-17:30

Discussion

JOINT 1

IASL & Africa and Middle East

Jul. 16 17:40-17:55

HCV Elimination on Target - Lessons from Egypt

Imam Waked (National Liver Institute, Egypt)

Jul. 16 17:55-18:05

HCV - Reaching 2030 - Yes Rwanda Can!

Sabin Nzanzimana (Rwanda Biomedical Center, Rwanda)

Jul. 16 18:05-18:20

Mapping NAFLD Burden in the Middle East

Mohamed Elkassas (Helwan University, Egypt)

Jul. 16 18:20-18:30

MAFLD in SSA - Impending Doom or Unique Opportunity?

Mark Sonderup (University of Cape Town, South Africa)

Jul. 16 18:30-18:40

Upscaling HBV care in SSA - Can We Simply Do It?

Gibril Ndow (MRC Unit The Gambia at LSHTM, Gambia)

Jul. 16 18:40-18:50

HCC in SSA - Can We Do Better?

Edith Okeke (University of Jos, Nigeria)

Jul. 16 18:50-19:00

Project ECHO and NextGen Liver Education in SSA

Wendy Spearman (University of Cape Town, South Africa)

Jul. 16 19:00-19:20

Discussion

ROOM 2

Session 2

Global Perspectives on Liver Disease

Jul. 16 09:00-09:20

How to Lead a Team for Big Data Research?

Grace Wong (The Chinese University of Hong Kong, China)

Jul. 16 09:20-09:40

How to Overcome Pitfalls in Observational Studies

Young Suk Lim (University of Ulsan, Korea)

Jul. 16 09:40-10:00

AI Cutting-Edge Developments in Highly Developed Systems

Yock Yan Dan (National University Health System, Singapore)

Jul. 16 10:00-10:15

Personalized Medicine in Liver Diseases: "Present and Future"

Joost Drenth (Radboud University, Netherlands)

Jul. 16 10:15-10:40

Discussion

Session 4

Design of Clinical Trials for HBV Cure

Jul. 16 10:50-11:15

Early Response Indicators of Direct Antiviral Agents

Harry Janssen (University of Toronto, Canada)

Jul. 16 11:15-11:40

Immunological Correlates of Response to Treatments

Antonio Bertoletti (Duke-NUS Medical School, Singapore)

Jul. 16 11:40-12:05

Strategy of Combination Therapy

Man Fung Yuen (The University of Hong Kong, China)

Jul. 16 12:05-12:20

Discussion

Session 6

Academic Career Workshop

Jul. 16 14:00-14:20

How to Design and Conduct a Clinical Study?

Pei-Jer Chen (National Taiwan University, Taiwan)

Jul. 16 14:20-14:40

How to Present Orals and Posters in Congress?

Samuel Lee (University of Calgary, Canada)

Jul. 16 14:40-15:00

How to Write a Paper?

Paolo Angeli (University of Padova, Italy)

Jul. 16 15:00-15:20

Group Dynamics 101: How to Behave in and Lead Small or Large Groups?

Karin King (London School of Economics and Political Science, UK)

Jul. 16 15:20-15:40

Discussion

Session 8

Design of Clinical Trial for MAFLD

Jul. 16 15:50-16:10

Risk Stratification Algorithms for Referrals of Patients with MAFLD from Primary to Tertiary Care

Philip Newsome (University of Birmingham, UK)

Jul. 16 16:10-16:30

Non-Invasive Tests in Clinical Practice: Are They Useful and Are They Used

Vincent Wong (The Chinese University of Hong Kong, China)

Jul. 16 16:30-16:50

Innovative Clinical Trial Designs for MAFLD

Jacob George (University of Sydney, Australia)

Jul. 16 16:50-17:10

Multidisciplinary Management of NASH

Arun Sanyal (Virginia Commonwealth University School of Medicine, USA)

Jul. 16 17:10-17:30

Discussion